Ignite Creation Date:
2024-05-06 @ 4:09 PM
Last Modification Date:
2024-10-26 @ 2:05 PM
Study NCT ID:
NCT04895358
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-03-04
First Post:
2021-05-17
Brief Title:
Study of Pembrolizumab MK-3475 Plus Chemotherapy Versus Placebo Plus Chemotherapy for HRHER2- Locally Recurrent Inoperable or Metastatic Breast Cancer MK-3475-B49KEYNOTE-B49
Sponsor:
Organization:
Merck Sharp Dohme LLC